XGN Quote, Financials, Valuation and Earnings

Hypha Labs, Inc. has a net margin of -28.1% compared to Exagen, Inc.'s net margin of --. Exagen, Inc.'s return on equity of -137.47% beat Hypha Labs, Inc.'s return on equity of --.

Exagen, Inc. has a consensus price target of $9.50, signalling upside risk potential of 210.46%. On the other hand Hypha Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Exagen, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Exagen, Inc. is more attractive than Hypha Labs, Inc..

Exagen, Inc. has a beta of 1.935, which suggesting that the stock is 93.49% more volatile than S&P 500. In comparison Hypha Labs, Inc. has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.204%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hypha Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. Hypha Labs, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $16.6M, which are larger than Hypha Labs, Inc. quarterly revenues of --. Exagen, Inc.'s net income of -$4.7M is lower than Hypha Labs, Inc.'s net income of -$521.6K. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while Hypha Labs, Inc.'s PE ratio is 4.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.01x versus 1.16x for Hypha Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Interpace Biosciences, Inc. has a net margin of -28.1% compared to Exagen, Inc.'s net margin of 11.55%. Exagen, Inc.'s return on equity of -137.47% beat Interpace Biosciences, Inc.'s return on equity of --.

Exagen, Inc. has a consensus price target of $9.50, signalling upside risk potential of 210.46%. On the other hand Interpace Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 461.91%. Given that Interpace Biosciences, Inc. has higher upside potential than Exagen, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Exagen, Inc..

Exagen, Inc. has a beta of 1.935, which suggesting that the stock is 93.49% more volatile than S&P 500. In comparison Interpace Biosciences, Inc. has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.531%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Interpace Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. Interpace Biosciences, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $16.6M, which are larger than Interpace Biosciences, Inc. quarterly revenues of $8.8M. Exagen, Inc.'s net income of -$4.7M is lower than Interpace Biosciences, Inc.'s net income of $1M. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while Interpace Biosciences, Inc.'s PE ratio is 2.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.01x versus 1.11x for Interpace Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of -28.1% compared to Exagen, Inc.'s net margin of 16.13%. Exagen, Inc.'s return on equity of -137.47% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.21%.

Exagen, Inc. has a consensus price target of $9.50, signalling upside risk potential of 210.46%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $661.40 which suggests that it could grow by 34.58%. Given that Exagen, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Exagen, Inc. is more attractive than Thermo Fisher Scientific, Inc..

Exagen, Inc. has a beta of 1.935, which suggesting that the stock is 93.49% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.077%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.36% to investors and pays a quarterly dividend of $0.47 per share. Exagen, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exagen, Inc. quarterly revenues are $16.6M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. Exagen, Inc.'s net income of -$4.7M is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while Thermo Fisher Scientific, Inc.'s PE ratio is 27.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.01x versus 4.14x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of -28.1% compared to Exagen, Inc.'s net margin of -2.87%. Exagen, Inc.'s return on equity of -137.47% beat XWELL, Inc.'s return on equity of -224.93%.

Exagen, Inc. has a consensus price target of $9.50, signalling upside risk potential of 210.46%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 554.21%. Given that XWELL, Inc. has higher upside potential than Exagen, Inc., analysts believe XWELL, Inc. is more attractive than Exagen, Inc..

Exagen, Inc. has a beta of 1.935, which suggesting that the stock is 93.49% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 0.959, suggesting its less volatile than the S&P 500 by 4.053%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $16.6M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Exagen, Inc.'s net income of -$4.7M is lower than XWELL, Inc.'s net income of -$211K. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.01x versus 0.21x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.